These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 36620596)
21. A cuproptosis-related lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma. Wu J; Yao J; Jia S; Yao X; Shao J; Cao W; Ma S; Yao X; Li H Heliyon; 2023 Sep; 9(9):e19352. PubMed ID: 37810122 [TBL] [Abstract][Full Text] [Related]
22. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma. Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y Front Genet; 2023; 14():1039813. PubMed ID: 36755568 [TBL] [Abstract][Full Text] [Related]
23. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer. Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537 [TBL] [Abstract][Full Text] [Related]
24. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation. Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J Front Oncol; 2022; 12():1030802. PubMed ID: 36620545 [TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of cuproptosis-related lncRNAs in the prognosis and therapy response of patients with bladder cancer. Li D; Wu X; Fan X; Cheng C; Li D; Zhang W Ann Transl Med; 2022 Nov; 10(22):1232. PubMed ID: 36544685 [TBL] [Abstract][Full Text] [Related]
26. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z Front Genet; 2022; 13():947551. PubMed ID: 35938003 [No Abstract] [Full Text] [Related]
27. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis. Li D; Wu X; Song W; Cheng C; Hao L; Zhang W Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675 [TBL] [Abstract][Full Text] [Related]
28. Prediction of prognosis, immune infiltration, and personalized treatment of hepatocellular carcinoma by analysis of cuproptosis-related long noncoding RNAs and verification Li S; Zhu Z; Lu J; Cao W; Song F; Xiao C; Zhang P; He Z; Weng J; Xu J Front Oncol; 2023; 13():1159126. PubMed ID: 37746284 [TBL] [Abstract][Full Text] [Related]
29. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L Front Genet; 2023; 14():1056000. PubMed ID: 36845390 [No Abstract] [Full Text] [Related]
30. Cuproptosis-related lncRNAs predict prognosis and immune response of thyroid carcinoma. Shi Y; Sheng P; Guo M; Chen K; Zhou H; Wu M; Li W; Li B Front Genet; 2023; 14():1100909. PubMed ID: 37470034 [No Abstract] [Full Text] [Related]
31. Development and validation of a novel endoplasmic reticulum stress-related lncRNA prognostic signature and candidate drugs in breast cancer. Cai J; Ji Z; Wu J; Chen L; Zheng D; Chen Y; Zhang X; Xie W; Huang J; Chen M; Lin R; Lin W; Chen Y; Li Z Front Genet; 2022; 13():949314. PubMed ID: 36092873 [TBL] [Abstract][Full Text] [Related]
32. The cuproptosis-related signature predicts prognosis and indicates immune microenvironment in breast cancer. Li J; Wu F; Li C; Sun S; Feng C; Wu H; Chen X; Wang W; Zhang Y; Liu M; Liu X; Cai Y; Jia Y; Qiao H; Zhang Y; Zhang S Front Genet; 2022; 13():977322. PubMed ID: 36226193 [TBL] [Abstract][Full Text] [Related]
33. A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients. Jiang S; Zhang J; Fan Q; Li Z; Dou R; Lin Z; Chen Z; Xu Y; Huang Z; Lan J; Lin W; Xu S; Gao X; Li M Hum Cell; 2023 Mar; 36(2):798-811. PubMed ID: 36709471 [TBL] [Abstract][Full Text] [Related]
34. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma. Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235 [TBL] [Abstract][Full Text] [Related]
35. Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis. Li H; Jiang H; Huang Z; Chen Z; Chen N Aging (Albany NY); 2023 Aug; 15(16):8325-8344. PubMed ID: 37616061 [TBL] [Abstract][Full Text] [Related]
36. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer. Bai Y; Zhang Q; Liu F; Quan J Front Immunol; 2022; 13():1027449. PubMed ID: 36451815 [TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in colorectal cancer. Zhu Z; Zhao Q; Li S; Weng J; Guo T; Zhu C; Xu Y Front Genet; 2022; 13():984743. PubMed ID: 36467996 [No Abstract] [Full Text] [Related]
38. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs. Tu H; Zhang Q; Xue L; Bao J Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481 [TBL] [Abstract][Full Text] [Related]
39. Construction of prognostic signature of breast cancer based on N7-Methylguanosine-Related LncRNAs and prediction of immune response. Cao J; Liang Y; Gu JJ; Huang Y; Wang B Front Genet; 2022; 13():991162. PubMed ID: 36353118 [No Abstract] [Full Text] [Related]
40. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma. Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]